ArticleFrontiers in physiology2026
Sodium butyrate attenuates D-galactose-induced cellular senescence in WI-38 fibroblasts
Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cellular senescence is closely associated with various age-related diseases. Sodium butyrate (NaB), a short-chain fatty acid and histone deacetylase (HDAC) inhibitor, exhibits potential anti-aging properties; however, its precise mechanisms remain unclear. This study aimed to investigate the protective effects of NaB against D-galactose (D-gal)-induced senescence in WI-38 human fibroblasts and elucidate the underlying mechanisms. WI-38 cells were co-treated with D-gal and NaB simultaneously to investigate whether NaB could mitigate D-gal-induced senescent changes. Senescence phenotypes were assessed by SA-β-Gal staining, ROS detection, and ELISA. Western blotting and chromatin immunoprecipitation-quantitative PCR (ChIP-qPCR) were performed to evaluate signaling pathways and histone acetylation, while siRNA knockdown validated Nrf2 function. NaB dose-dependently reduced SA-β-Gal-positive cells, ROS levels, and MDA content, while restoring SOD and GSH-Px activities and suppressing IL-6 and IL-1β secretion. Mechanistically, NaB promoted Nrf2 nuclear translocation by downregulating Keap1, thereby upregulating HO-1 and NQO1 expression. NaB also inhibited p53 phosphorylation and reduced p21 and p16 expression at both the mRNA and protein levels, as confirmed by RT-qPCR and Western blotting. Furthermore, NaB suppressed HDAC activity and restored H3K9ac and H3K27ac levels. Nrf2 knockdown reversed NaB's protective effects. ChIP-qPCR revealed that NaB restored H3K9ac enrichment at p21 and p16 promoters. These results indicate that NaB may attenuate D-gal-induced cellular senescence through coordinated modulation of the Nrf2/ARE pathway, p53/p21/p16 signaling, and HDAC-mediated epigenetic regulation. These findings provide preliminary evidence supporting NaB as a candidate modulator of aging-associated cellular processes, warranting further validation
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.